John G. Hodgson

John G. Hodgson's AcademicInfluence.com Rankings

John G. Hodgson

Biology

#14387

World Rank

#18122

Historical Rank

Computational Biology

#347

World Rank

#348

Historical Rank

Genetics

#1639

World Rank

#1747

Historical Rank

Molecular Biology

#2455

World Rank

#2493

Historical Rank

biology Degrees

Download Badge

Biology

John G. Hodgson's Degrees

PhD Biochemistry Stanford University

Why Is John G. Hodgson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John G. Hodgson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

DNA chips: An array of possibilities (1998) (410)
ADMET—turning chemicals into drugs (2001) (317)
Sward measurement handbook (1993) (132)
The pandemic pipeline (2020) (115)
Monarch Bt-corn paper questioned (1999) (66)
Expression Systems: A User's Guide (1993) (54)
The Changing Bulk Biocatalyst Market (1994) (48)
The Good, the Bad, and the Indifferent (1993) (43)
Light, Angles, Action (1994) (35)
To Treat or Not to Treat: That Is the Question for Serum (1995) (35)
Carbohydrate-Based Therapeutics (1991) (32)
Shrinking DNA diagnostics to fill the markets of the future (1998) (28)
Pharmacogenomics: Will the regulators approve? (1998) (28)
Fetal Bovine Serum Revisited (1993) (27)
It's the real thing (1999) (27)
Scientists avert new GMO crisis (2000) (26)
Remodeling MMPIs (1995) (25)
The price of everything (1999) (24)
Bulk Amino–Acid Fermentation: Technology and Commodity Trading (1994) (17)
Checking Sources: The Serum Supply Secret (1991) (16)
WHO guidelines presage US biosimilars legislation? (2009) (15)
Public biotech 2010—the numbers (2011) (15)
Biosafety rules get thumbs up (2000) (15)
Pharmacogenomics: Will the regulators approve? (1998) (15)
Still Waters Run Deep (1994) (15)
Crystal gazing the new biotechnologies (2000) (14)
Public biotech 2008—the numbers (2009) (14)
Public biotech 2009—the numbers (2010) (14)
Doubts linger over Mexican corn analysis (2002) (13)
Private biotech 2004—the numbers (2006) (12)
All clear for HIV-targeting ribozyme in phase II. (1998) (11)
Vive la France (2001) (11)
Refreshing the biologic pipeline 2020 (2021) (11)
Biotechnology: Feeding the World? (1992) (10)
National politicians block GM progress (2000) (10)
LION and Degussa apply genomics to fermentation (1998) (9)
Receptor Screening and the Search for New Pharmaceuticals (1992) (9)
A genetic heritage betrayed or empowered? (1998) (9)
Making Monoclonals in Microbes (1991) (9)
Expression systems: a user's guide. Emphasis has shifted from the vector construct to the host organism. (1993) (8)
Molecular Biology in 2001 (1990) (8)
Biotechnology Regulation in Europe (1991) (8)
The engineers of change (2002) (7)
Pharmaceutical Screening: From Off-the-Wall to Off-the-Shelf (1993) (7)
Maize uncertainties create political fallout (2002) (7)
Whole Animals for Wholesale Protein Production (1992) (7)
Light, angles, action. Instruments for label-free, real-time monitoring of intermolecular interactions. (1994) (7)
One for the Record Books (1993) (7)
Scientists cry foul as Europe plays politics with GM crops (2008) (6)
New Formulas for Carbohydrates (1995) (6)
EC Policy: Harmonize or Compromise? (1991) (6)
Traders predict biodiversity turmoil (2000) (5)
Controlling Chirality in Enzymatic Synthesis (1992) (5)
Europe, Maastricht, and Biotechnology (1992) (5)
Nutraceuticals tread business tightrope in Europe (2002) (5)
Analysts, firms pour cold water on SNP Consortium (1999) (5)
EC says 1% is acceptable GMO "contamination" (1999) (4)
First Genetic Trust banks on genes (2000) (4)
When biotech goes bad (2016) (4)
Public biotechnology companies earn $12.4billion, spend $5.2 billion (1997) (4)
Antisense companies reach reality (1996) (4)
Iceland considers its genetic future (1998) (4)
Genome Mapping the “Easy” Way (1994) (4)
UK keen to mimic German venture scheme (2001) (4)
US study shows GM pros (1999) (4)
Centrifugation Takes a New Turn (1991) (4)
Chromatography of Complex Carbohydrates (1991) (4)
Data-Directed Drug Design (1991) (4)
Biotechnology—a year of living prosperously (1997) (3)
deCODE looks forward as database law passes (1999) (3)
Reply to “Hazardous CaMV promoter?” (2000) (3)
Dolly opens a farm full of possibilities (1997) (3)
Curagen lays down markers, 120,000 of them (1999) (3)
Affinity innovations for bioprocessing. (1990) (3)
Capitalizing on Carbohydrates (1990) (3)
UK Sweet on Engineered Yeast (1990) (3)
Hyseq–Variagenics merger signals end of the line (2003) (3)
Elective Affinities: The Art of Chromatography (1992) (3)
Thousands of amyloids may foil Alzheimer’s drugs (2019) (3)
Heliosynthese takes on Martek infant formula market (1996) (3)
Does Biotechnology Measure Up? (1993) (3)
Prestidigitation in the Clinic (1993) (3)
EC struggles to unravel regulations (2000) (3)
Fetal bovine serum revisited. A year ago serum regulations were a hodgepodge. Has anything changed? (1993) (3)
Europeans Standardize DNA Profiles (1990) (3)
[euro]2 billion IMI launched with European pharma (2008) (3)
South Africa seeks genomic partners (2001) (3)
Moratorium hits Danish companies (2000) (3)
Reconstructing pharmaceutical instinct (2002) (3)
Critics slam new Monarch Bt-corn data (2000) (3)
Cancer prognostic approved. (1998) (2)
Biotech's Platform Technologies Lure Big Pharma (1995) (2)
Public biotech: The numbers (1998) (2)
New Frontiers for Mass Spectrometry (1990) (2)
Life sciences firms cheer unlocking of National Health Service (2011) (2)
Protein Engineers: Better than Nature, Faster than Evolution (1992) (2)
Building a common future (1999) (2)
Substitutes For Human Blood (1991) (2)
Infectech's game plan (1999) (2)
Industry still fears political opposition to European Union GM legislation (2000) (2)
Obesity: Where Less Is More (1995) (2)
The engineer in the garden: by C. Tudge Jonathan Cape, London, 1993. £17.99 hbk (xii + 398 pages) ISBN 0 224 03826 5 (1994) (2)
RNA epigenetics spurs investor interest, but uncertainties linger (2018) (2)
French loan arranger seeks biotech posse (2001) (2)
Gone, butt not begotten (2000) (2)
Genentech trade secrets theft highlights risk for biotechs (2019) (2)
The shifting center of human genome mapping (1996) (2)
Patent case unblocks antibody businesses (1999) (2)
Cell Culture Over-Sold (1991) (2)
Ten years of biotech gaffes (2006) (2)
Geneticism and freedom of choice (1989) (2)
Before anyone knew the future nature of biotechnology (1998) (2)
Shutters come off IPO window (2002) (2)
Bayer lapse exposes pharma's vulnerability (2001) (2)
BSE Scares Up a Host of Source Worries (1990) (2)
Sequencing and Mapping Efforts in “Model Organisms” (1992) (2)
GMO roundup (2000) (2)
New Ways to Cleave Nucleic Acids (1990) (1)
Market Infiltration in Filtration (1990) (1)
Eurobiotech Trails U.S. R&D Spending (1991) (1)
The Whys and Wherefores of DNA Amplification (1993) (1)
Companies Battle Over Nicotine Patch (1992) (1)
Public biotech 99: the numbers (2000) (1)
Patenting IL-6 (1992) (1)
UK's Ciba maize decision “political”? (1997) (1)
Some Success with Autologous Gene Therapy (1990) (1)
Towards dialogue in the recombinant DNA controversy (1988) (1)
Mexico to relax rDNA ban? (2002) (1)
European Biopharmaceutical Culture (1990) (1)
From Clone to Controversy (1990) (1)
European Advisory Group Bares Its Teeth (1990) (1)
Rice and the Greenpeace counterrevolutionaries (1996) (1)
GlaxoWellcome and MDL become entangled in the Web (1996) (1)
European Parliament vote encourages industry to proclaim green biotech (2002) (1)
New tech transfer models gain traction with deal flow (2010) (1)
British Bio-tech Raises £40 Million (1991) (1)
Companies earn $10 billion of biotech's $30 billion (1996) (1)
Public companies get creative in raising finance (2010) (1)
Process Validation in the Electronic Age (1994) (1)
To treat or not to treat: that is the question for serum: as regulations on serum importation stagnate, the industry moves toward treatment options (1995) (1)
Protein Design: Rules, Empiricism, & Nature (1990) (1)
No deliberate release in Europe (1989) (1)
Towards dialogue in the recombinant DNA controversy. (1988) (1)
New “deCODE bill” restarts controversy (1998) (1)
The habits of successful bioentrepreneurs. (2003) (1)
FoE urges UK to disclose more of GM crop trial data (2001) (1)
Biotechnology: Changing the Way Nature Works (1990) (1)
Making the Transition to Applied Technology (1990) (1)
GM roundup (1999) (1)
Proleukin Slowing the CPMP Merry-Go-Round (1990) (1)
Bulgaria gets Eastern Europe's first gene release body (1996) (1)
Electrophoresis in Thin Air (1992) (1)
Assessing progress in biotech’s gender balance (2019) (1)
The First of the Big Spenders (1992) (1)
Johnson &Johnson acquires Centocor (1999) (1)
The Hard Reality (1992) (1)
The $802 million fallacy (2004) (1)
Appropriate Biotech for Africa (1990) (1)
Europeans Feel U.S. Squeeze (1990) (1)
20 years of Nature Biotechnology biomedical research (2016) (1)
Peptides No Small Thing To Danish Co. (1991) (1)
Marketing a global technology (1989) (1)
Corning chips in (2000) (1)
Biotech stocks cushioned from Cephalon setback (1996) (0)
Nuffield Council dishes up biotech report (1999) (0)
GMO roundup (2000) (0)
Favoring Rhone–Poulenc? (1991) (0)
Kick-start for Canada's agbio (2009) (0)
Get Accredited (1991) (0)
The Nature Biotechnology 2001 New Year quiz (2001) (0)
Two SNP deals for Gemini (2000) (0)
Yeast: A sequence model, not a management one (1996) (0)
Micro-Imaging: In Vivo Veritas (1991) (0)
Maize faces new hurdle in EU (1998) (0)
EU food agency circles round biotech (1999) (0)
The Nature Biotechnology 2002 New Year quiz (2002) (0)
Mastering Biology (1991) (0)
The irrationality precedent (2005) (0)
Cortecs Whets Some Appetites (1990) (0)
Trimmed down Chiron pitches cancer genomics (1998) (0)
Investment indicators show US is still ahead (1998) (0)
Erratum: When biotech goes bad (2016) (0)
AHP sells Immunex stake (2000) (0)
Making magnets to global biotechnology people (1998) (0)
BRITECH R&D fund (1999) (0)
GMO fudge at BIA bash (2000) (0)
GFP: Kacs and dogs (1999) (0)
The Ins and Outs of Electrophoresis (1993) (0)
Putting the “Pep” in Peptides (1993) (0)
Mapping the Genome (2003) (0)
Ambitious French biotech plan faces EU hurdle (2003) (0)
European Patent Rules Emerge (1992) (0)
BIA drafts code of practice (1999) (0)
The Culture of Cryopreservation (1994) (0)
Efficacy of UK smallpox vaccine questioned (2002) (0)
Wellcome Reaches Outward and Upward (1995) (0)
Drug pipeline 4Q22 — sticking around (2023) (0)
GMO roundup (2000) (0)
UK allows genetic testing (2000) (0)
Immunex Sues Hoechst Over GM–CSF (1992) (0)
Peace and Biotechnology in the Middle East (1993) (0)
The Lancet in GMO dispute (1999) (0)
Amgen lists on Easdaq (2000) (0)
The rise and fall and rise of CBC (1996) (0)
GM roundup (1999) (0)
Germany hit badly by investor disinterest (2002) (0)
UK interest groups take all sides of GM issue (1999) (0)
European Plant Biotech Week bids for limelight (1997) (0)
Degrees of separation (2000) (0)
A certain lack of co-ordination (1987) (0)
Erratum: Public biotech 2009—the numbers (2010) (0)
Proteins, biotechnology and Society (1988) (0)
GM roundup (1999) (0)
EC–FDA mutual recognition agreement proves difficult (1997) (0)
Affymetrix spins off firm (2000) (0)
An Appetite for Technology: Hoffmann–La Roche (1992) (0)
Strugglers may drop through Nasdaq net (1997) (0)
Fallout from the merger that might be (1999) (0)
Drug makers chase anti-flu pill (2019) (0)
Thousands of amyloids may foil Alzheimer’s drugs (2019) (0)
Differentiating data and information (1997) (0)
Assessing progress in biotech’s gender balance (2019) (0)
Ownership First (1992) (0)
The good, the bad, and the indifferent. A story of protein structure (mis)interpretation that unfolds with every new beta-turn. (1993) (0)
FACTS AND FEATS OF THE BIOTECH BUSINESS (1993) (0)
Validating a business model (2000) (0)
Federation Still Fragmented (1990) (0)
Euro biotech report adds to paper mountain (2001) (0)
Millennium collaborates with leading clinical centers (1998) (0)
The Worldview national ranking of health biotech sectors (2022) (0)
The Nature Biotechnology 2000 Millennial quiz (2000) (0)
GM health food (2000) (0)
Ciba disqualified by minority (1996) (0)
Drug makers chase anti-flu pill (2019) (0)
The 802 million dollars fallacy. (2004) (0)
Protein Conformity and Conformation (1991) (0)
MRA agreement signals start of global harmonization (1997) (0)
Markl opens Max-Planck's doors (1997) (0)
Denmark Bans Use of Testing Info (1991) (0)
EU attempts to streamline biotech “vision” (2001) (0)
The editor replies (1989) (0)
Mouse MS Induced by MHC Class I Expression (1990) (0)
US says no to GM labels (1999) (0)
On Deck: The European Union (1994) (0)
John Hodgson responds: Software on the Internet (1996) (0)
Hypertexting through the Regulations (1992) (0)
The advisory committee strikes back (2000) (0)
Double standards in GMP deduplication row (1996) (0)
GMO roundup (2000) (0)
Call for reaction … and action (1989) (0)
Celltech, Chiroscience fire merger gun (1999) (0)
GMO roundup (2001) (0)
Swiss Pass Biotech Referendum (1992) (0)
Hoechst Decision Spurs Action (1990) (0)
Porton to Pluck Government Research Plum (1990) (0)
Field testing following notification (1995) (0)
UNEP “buys support for Cartagena,” say critics (2002) (0)
What Form for Eurobioinformatics? (1992) (0)
European biotechnology governance seizes up (1999) (0)
GMO roundup (2000) (0)
Pro-GMO ministers sidelined (1999) (0)
GMO roundup (2000) (0)
Chromatography: Separation and Purification (1993) (0)
The Nature Biotechnology 1999 New Year quiz (1999) (0)
Chemical short-cuts (1988) (0)
CAT's phage technology patent upheld (2000) (0)
Seeking Sugar Daddy (1992) (0)
Immunogenetics for Rheumatoid Arthritis (1990) (0)
FDA Nixes Xoma's Sepsis Antibody (1992) (0)
Assays a La Photolithography (1991) (0)
Publisher Correction: CRISPR target prediction remains blunt tool for clinical applications (2019) (0)
Cloning opera (2000) (0)
UK government blows a hollow trumpet (1996) (0)
From Little Acorns… (1995) (0)
Prestidigitation in the clinic. "Magic bullets"--are they homing in on disease or just inducing HAMA horror? (1993) (0)
Europe needs a single, deep capital market (2002) (0)
GM roundup (1999) (0)
GM roundup (2000) (0)
Release and Regulations (1993) (0)
Publisher Correction: Biotech’s baby boom (2019) (0)
Fermentation and Cell Culture (1993) (0)
There's a Whole Lot of Nothing Going On (1995) (0)
Scios Buys Nova Pharmaceutical (1992) (0)
CRISPR target prediction remains blunt tool for clinical applications (2019) (0)
Business and Regulatory News (1998) (0)
Schering Acquires a Taste for Biotechnology (1990) (0)
Separating the microfuges (1998) (0)
GMO roundup (2000) (0)
2022 – toughing out the trough (2023) (0)
Rapigene bargain buy for Qiagen (2000) (0)
Growing Biotechnology at the Fringes (1995) (0)
The Emergence of Biotechnology in Israel (1994) (0)
Vector May Help Direct Oxford Virology (1991) (0)
CRISPR target prediction remains blunt tool for clinical applications (2019) (0)
Stirring the Fermentor of Peace (1994) (0)
New-Food rules (1992) (0)
GMO roundup (2000) (0)
Genes, means and ends (1987) (0)
GMO roundup (1999) (0)
A Word or Two from the Wise (1993) (0)
Peptide Synthesis Gets Friendly (1991) (0)
Euro indecision triggers food anarchy (1997) (0)
Treating ADA in Europe (1990) (0)
GMO Roundup (2000) (0)
Unified Approvals, Standards (1991) (0)
Technology Transfer (1992) (0)
Will Celltech Move Back to the Future? (1990) (0)
Publisher Correction: Biotech’s baby boom (2019) (0)
Public companies spend over $4 billion on R&D (1996) (0)
Getting to Know the Glycogen (1992) (0)
Does Less Mean More for the Genome Projects? (1995) (0)
Yes, But….. (1991) (0)
Slew Of Biotech Alliances (1992) (0)
Net to help catch NZ serum forgers (1998) (0)
Annuaire De La Bio-Industrie Et Des Biotechnologies 1985: Biofutur, 1985. 400 FF (9 + 283 pages) (1985) (0)
EC Industrial Policy Efforts Inch Forward (1990) (0)
Dutch Regulations Now in Force (1990) (0)
Gene therapy buy (2000) (0)
GMO roundup (2000) (0)
Cephalon acquires Anesta (2000) (0)
Tips for your pipette (1997) (0)
Sequenom patent and deal (1999) (0)
Myotrophin: “spectacular” or “snake oil” (1996) (0)
TTO patent swap (2010) (0)
Insect rules take shape (1995) (0)
Either DNA or protein, dummy (1998) (0)
Patenting processes and prior publication (1989) (0)

This paper list is powered by the following services:

John G. Hodgson's Academic­Influence.com Rankings

John G. Hodgson's Degrees

Why Is John G. Hodgson Influential?

John G. Hodgson's Published Works

Published Works

John G. Hodgson's AcademicInfluence.com Rankings